Inicio>>Signaling Pathways>> Tyrosine Kinase>> VEGFR>>VEGFR Tyrosine Kinase Inhibitor II

VEGFR Tyrosine Kinase Inhibitor II (Synonyms: Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II)

Catalog No.GC16062

VEGFR Tyrosine Kinase Inhibitor II (compuesto 3) es un potente inhibidor de la angiogénesis con IC50 de 0,02, 0,18, 0,24 7,3 y 7 μM para KDR, Flt-1, c-Kit, EGF-R y c-Src, respectivamente .

Products are for research use only. Not for human use. We do not sell to patients.

VEGFR Tyrosine Kinase Inhibitor II Chemical Structure

Cas No.: 269390-69-4

Tamaño Precio Disponibilidad Cantidad
1mg
87,00 $
Disponible
5mg
253,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

VEGFR tyrosine kinase inhibitor II is a pyridinyl-anthranilamide compound that inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC50s = 20, 180, and 240 nM, respectively).1 It displays minimal activity against c-Src and EGFR (IC50s = 7 and 7.3 µM, respectively) and is inactive against Cdk1, c-Met, IGF-1R, and PKA (IC50s > 10 µM).1 VEGFR tyrosine kinase inhibitor II has been investigated for its potential to inhibit tumor induced angiogenesis.[1]

Reference:
[1] Furet, P., Bold, G., Hofmann, F., et al. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorganic & Medicinal Chemistry Letters 13(18), 2967-2971 (2003).

Reseñas

Review for VEGFR Tyrosine Kinase Inhibitor II

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for VEGFR Tyrosine Kinase Inhibitor II

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.